RxDoctor Payments Data

Tara Harris

Psychiatric/Mental Health · Greensboro, NCNPI 1851575930

Payments from drug & device makers

$1,645in general payments, 2019–2025

Across 77 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$678
  • Otsuka America Pharmaceutical, Inc.$226
  • Abbott$120
  • E.r. Squibb & Sons, L.L.C.$119
  • Urovant Sciences Inc$103
  • Boehringer Ingelheim$69
  • plus $332 from 12 others

What the payments were for

  • Food & beverage$1,645100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,645 in reported general payments places this provider in the 75th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$9,120
Medicare patients
40
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$33,787
FarxigaDapagliflozin Propanediol13$6,672
MyrbetriqMirabegron13$5,939
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,205
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide25$1,245
Levothyroxine Sodium95$1,050
Omeprazole64$945
Atorvastatin Calcium118$856
Gabapentin55$824
Metoprolol Succinate50$746
Pravastatin Sodium51$610
Losartan Potassium53$601
Amlodipine Besylate131$566
Glimepiride17$540
Rosuvastatin Calcium54$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$678$33,78732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →